ASND
Ascendis Pharma A/SPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 8 ▲ Ascendis Pharma announced Week 52 data from its Phase 2 COACH trial…
- May 11 ▼ 1 insider sell $4.6M at $238.49
- May 26 to Jun 2 ▲ 3 days of insider buys: $284.4K by 2 insiders, avg $227.53
- Jun 30 ▲ 29 funds open new positions (13F)
- Aug 14 ▲ 1 insider buy $492.7K at $246.33
- Sep 2 to Sep 8 ▼ 2 days of insider sells: $872.9K by 2 insiders, avg $269.75
- Sep 9 FDA: First Infant Data from Ascendis Trial of Once-Weekly Trans…
- Sep 14 ▲ Buyback: Ascendis Announces Planned $400 Million Share Repurchase P…
- Sep 15 ▼ Raymond James downgrades
- Oct 16 ▲ Ascendis Pharma announced that the EMA's CHMP adopted a positive opi…
- Nov 6 ▲ Ascendis Pharma announced that the EMA's COMP adopted a positive opi…
- Nov 12 ▲ Ascendis Pharma reported Q3 2026 product revenue of EUR 366M (+89% Y…
Signal stack
Where each data set points today.
- InsidersBEARISH
2 insiders bought $777.1K at an average $239.10. 3 insiders sold $5.5M. Price is 14% above their cost.
- InstitutionsBULLISH
Q2 2026: 35 added (29 new), 12 trimmed or exited. Largest new: Westfield Capital Management $1.3B, American Century Companies $373.6M.
- AnalystsBULLISH
27 of 28 rate it Buy or better.
- EstimatesRISING
Current-quarter EPS estimate $1.177 → $1.900 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest −4.3% to 3.00M shares. 5.0 days to cover, ≈4.5% of shares.
- TrendUPTREND
12% above its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| WESTFIELD CAPITAL MANAGEMENT CO LP | NEW | $1.3B |
| BlackRock, Inc. | DOUBLED | $589.9M |
| AMERICAN CENTURY COMPANIES INC | NEW | $373.6M |
| PRICE T ROWE ASSOCIATES INC /MD/ | TRIM | $299.4M |
| PRINCIPAL FINANCIAL GROUP INC | NEW | $233.0M |
| STATE STREET CORP | DOUBLED | $137.1M |
| GEODE CAPITAL MANAGEMENT, LLC | NEW | $107.5M |
| UBS Group AG | NEW | $107.2M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
28 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Nov 13, 2026 | UBS MAINTAIN | Buy |
| Nov 13, 2026 | Wells Fargo MAINTAIN | Overweight |
| Nov 13, 2026 | RBC Capital REITERATE | Outperform |
| Nov 13, 2026 | TD Cowen MAINTAIN | Buy |
| Nov 13, 2026 | Evercore ISI Group MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Bodenhoff Mads SVP & PAO Sep 8, 2026 | SELL | $810.6K |
Bodenhoff Mads SVP & PAO Sep 8, 2026 | EXERCISE | $330.0K |
HOLTUG LARS Director Sep 2, 2026 | SELL | $62.3K |
BIENAIME JEAN JACQUES Director Aug 14, 2026 | BUY | $270.4K |
BIENAIME JEAN JACQUES Director Aug 14, 2026 | BUY | $222.2K |
SMITH SCOTT THOMAS EVP & Chief Financial Officer Jun 2, 2026 | BUY | $21.9K |
BIENAIME JEAN JACQUES Director May 29, 2026 | BUY | $22.4K |
BIENAIME JEAN JACQUES Director May 29, 2026 | BUY | $44.5K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $1.90 | $1.57–$2.71 | +64.3% | $414.8M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
35 filings · 6 press releases · 21 bullish · 1 bearish · 13 neutral- NEUTRAL SC 13G/ANov 16, 2026
T. Rowe Price Investment Management filed an amended Schedule 13G disclosing beneficial ownership of 8,194,812 ADR shares of Ascendis Pharma as of September 30, 2026, representing 12.4% of the class. This is an increase from the prior filing (FMR LLC at 5.2%), indicating T. Rowe Price added to its…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 6-KNov 12, 2026
Ascendis Pharma filed its updated Articles of Association and disclosed a routine grant of 28,030…
This is a routine employee incentive grant with negligible dilution. No trading signal. Monitor upcoming quarterly results for revenue and pipeline progress.
- BULLISH 6-KNov 12, 2026
Ascendis Pharma reported Q3 2026 product revenue of EUR 366M (+89% YoY), driven by YORVIPATH (EUR…
Watch for the final EC decision on TransCon CNP in Q4 2026, which would open the EU market and drive further revenue growth. Monitor YUVIWEL patient enrollment trajectory and reimbursement expansion…
- NEUTRAL PRESS-RELEASENov 12, 2026
Ascendis Pharma reported Q3 2026 product revenue of €366M (+89% YoY), driven by YORVIPATH (€291M…
The EPS miss relative to consensus may weigh on near-term sentiment, but the strong revenue growth, first operating profit, and positive regulatory catalyst (TransCon CNP EU decision) provide a…
All ASND filing & press-release reports (41)
- SC 13G/A reportNov 16, 2026
- 6-K reportNov 12, 2026
- 6-K reportNov 12, 2026
- PRESS-RELEASE reportNov 12, 2026
- 6-K reportNov 6, 2026
- PRESS-RELEASE reportNov 6, 2026
- SC 13G/A reportNov 5, 2026
- INST-CLUSTER reportNov 2, 2026
- 6-K reportOct 26, 2026
- 6-K reportOct 16, 2026
- 6-K reportOct 14, 2026
- INST-CLUSTER reportSep 22, 2026
- CLUSTER reportSep 9, 2026
- HC Wainwright & Co. initiates ASND to Buy, PT $345 (+31%)Aug 27, 2026
- 6-K reportAug 31, 2026
- BMO Capital initiates ASND to Outperform, PT $319 (+28%)Aug 19, 2026
- INSIDER-BUY reportAug 18, 2026
- 6-K reportAug 13, 2026
- PRESS-RELEASE reportAug 13, 2026
- 6-K reportAug 6, 2026
- PRESS-RELEASE reportAug 6, 2026
- 6-K reportJul 15, 2026
- 6-K reportJun 29, 2026
- 6-K reportJun 30, 2026
- PRESS-RELEASE reportJun 30, 2026
- 6-K reportJun 17, 2026
- 6-K reportJun 15, 2026
- PRESS-RELEASE reportJun 13, 2026
- 6-K reportJun 12, 2026
- CLUSTER reportJun 2, 2026
- Citigroup initiates ASND to Buy, PT $355 (+44.7%)May 19, 2026
- 6-K reportMay 7, 2026
- 6-K reportMay 7, 2026
- PRESS-RELEASE reportMay 6, 2026
- 6-K reportApr 21, 2026
- 6-K reportApr 8, 2026
- 6-K reportApr 8, 2026
- PRESS-RELEASE reportApr 8, 2026
- 6-K reportApr 7, 2026
- 3 reportApr 1, 2026
- PRESS-RELEASE reportMar 17, 2026